文献速递消化系统肿瘤

高敏感改良格拉斯哥预后评分对接受新辅助化疗的进展期胃癌患者疗效与预后的预测及预后意义

[Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

研究纳入117例接受SOX或mFOLFOX6新辅助化疗的进展期胃癌患者,按CRP和血清白蛋白计算HS-mGPS;HS-mGPS较高与更高T分期、淋巴结转移、远处转移、较低化疗总有效率和较低组织学反应率相关,且为DFS和OS的独立预后因素。

要点

  • HS-mGPS较高与更高T分期、N分期、M分期及较低化疗总有效率和组织学反应率相关(均P<0.05)。
  • 全组中位DFS为21.0个月(95%CI 6.4~35.6个月),中位OS为39.0个月(95%CI 21.4~56.6个月)。
  • HS-mGPS较高、N分期阳性及非R0切除与更差DFS和OS相关(均P<0.05)。

核心结论

  • HS-mGPS可用于预测进展期胃癌患者新辅助化疗的疗效,并可作为生存的独立预后因素。

研究设计与样本

  • 117例进展期胃癌患者术前接受SOX方案(奥沙利铂+替吉奥)或mFOLFOX6方案(奥沙利铂+亚叶酸钙+氟尿嘧啶)新辅助化疗。
  • 根据血C反应蛋白浓度和血清白蛋白水平计算HS-mGPS,分析其与临床病理特征的关系及影响预后的因素。

主要发现

  • 117例中ⅡB期43例、Ⅲ期60例、Ⅳ期14例;新辅助化疗后临床有效率为61.5%(72/117),疾病控制率为88.0%(103/117),组织学反应率为91.5%(107/117),R0切除率为81.2%(95/117)。
  • 全组中位DFS为21.0个月(95%CI 6.4~35.6个月),中位OS为39.0个月(95%CI 21.4~56.6个月)。
  • HS-mGPS较高与更高T分期、N分期、M分期、较低化疗总有效率和较低组织学反应率相关(均P<0.05)。
  • 单因素和多因素分析显示,HS-mGPS较高、N分期阳性及非R0切除与更差DFS和OS相关(均P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To study the predictive and prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) on the effect of neoadjuvant chemotherapy for advanced gastric cancer. Methods: 117 patients with advanced gastric cancer received neoadjuvant chemotherapy with SOX (oxaliplatin+ S1) or mFOLFOX 6(oxaliplatin+ CF+ 5-FU) regimen. HS-mGPS was calculated according to blood C-reactive protein (CRP) concentration and serum albumin (ALB) level. The correlation between HS-mGPS and clinicopathological characteristics was determined and the predictors of survival were analyzed. Results: 117 patients with stage ⅡB (43 cases), stage Ⅲ (60), and stage Ⅳ (14) received preoperative neoadjuvant chemotherapy. The overall response rate of neoadjuvant chemotherapy was 61.5%(72/117), and the tumor control rate was 88.0% (103/117), with a pathological response rate of 91.5% (107/117). The R0 resection rate was 81.2% (95/117). The median disease-free survival (DFS) was 21.0 (95% CI 6.4-35.6) months. The median overall survival (OS) was 39.0 (95% CI 21.4-56.6) months. Higher HS-mGPS was associated with higher T stage, local lymph-node metastasis, distant metastasis, lower chemotherapy overall response rate and lower pathological response rate (all P<0.05). The univariate analysis and multivariate analysis showed that higher HS-mGPS, presence of local lymph-node metastasis and non R0 resection were associated with poorer DFS and OS (P<0.05). Conclusion: HS-mGPS can be used to predict the benefits of neoadjuvant chemotherapy and as an independent prognostic factor for survival in patients with advanced gastric cancer. 目的: 探讨高敏感格拉斯哥评分(HS-mGPS)对进展期胃癌患者新辅助化疗疗效和预后的预测作用。 方法: 117例进展期胃癌患者术前接受SOX方案(奥沙利铂+替吉奥)或mFOLFOX6方案(奥沙利铂+亚叶酸钙+氟尿嘧啶)新辅助化疗,根据C反应蛋白(CRP)和血清白蛋白(ALB)水平计算HS-mGPS,分析HS-mGPS与进展期胃癌患者临床病理特征的关系以及影响新辅助化疗胃癌患者预后的因素。 结果: 117例接受新辅助化疗的进展期胃癌患者中,ⅡB期43例,Ⅲ期60例,Ⅳ期14例。新辅助化疗后的临床有效率为61.5%(72/117),疾病控制率为88.0%(103/117),组织学反应率为91.5%(107/117),R0切除率为81.2%(95/117)。全组患者的中位无病生存时间(DFS)为21.0个月(95%CI为6.4~35.6个月),中位总生存时间(OS)为39.0个月(95%CI为21.4~56.6个月)。HS-mGPS与进展期胃癌患者的T分期、N分期、M分期、化疗疗效和组织学反应有关(均P<0.05)。单因素和多因素分析显示,HS-mGPS、N分期和R0切除是影响进展期胃癌患者中位DFS和OS的独立因素(均P<0.05)。 结论: HS-mGPS可用于预测胃癌新辅助化疗的疗效和预后。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Cui Y, Li J, Cao YH, et al. [Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28316218. doi:10.3760/cma.j.issn.0253-3766.2017.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。